Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI

Digestive Diseases

Volumn 30, Issue 6, 2012, Pages 617-622

  Bae, Kyung Eun ^a   Kim, So Yeon ^a   Lee, Seung Soo ^a   Kim, Kyoung Won ^a   Won, Hyung Jin ^a   Shin, Yong Moon ^a   Kim, Pyo Nyun ^a   Lee, Moon Gyu ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Gd EOB DTPA; Hepatic function; Liver MR

Indexed keywords

GADOXETIC ACID;

BILE DUCT; BILE FLOW; CLEARANCE; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; HEPATIC EXTRACTION FRACTION; HEPATOCELLULAR UPTAKE INDEX; HUMAN; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER PARENCHYMA; MAGNETIC RESONANCE RELAXOMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; SIGNAL NOISE RATIO;

CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER; LIVER DISEASES; MAGNETIC RESONANCE IMAGING;

EID: 84871828032     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000343092     Document Type: Conference Paper

References (44)

1. Zipprich A, Kuss O, Rogowski S, Kleber G, Lotterer E, Seufferlein T, Fleig WE, Dollinger MM: Incorporating indocyanin green clearance into the model for end-stage liver disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis. Gut 2010; 59: 963-968.
2. Van den Broek MA, Olde Damink SW, Dejong CH, Lang H, Malago M, Jalan R, Saner FH: Liver failure after partial hepatic resection: Definition, pathophysiology, risk factors and treatment. Liver Int 2008; 28: 767-780. (Pubitemid 351818638)
3. Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, Hicks M, Alsfasser G, Lauwers G, Hawkins IF, Caridi J: Standardized measurement of the future liver remnant prior to extended liver resection: Methodology and clinical associations. Surgery 2000; 127: 512-519. (Pubitemid 30257509)
4. Morris-Stiff G, Gomez D, Prasad R: Quantitative assessment of hepatic function and its relevance to the liver surgeon. J Gastrointest Surg 2009; 13: 374-385.
5. Kwon AH, Matsui Y, Ha-Kawa SK, Kamiyama Y: Functional hepatic volume measured by technetium-99m-galactosyl-human serum albumin liver scintigraphy: Comparison between hepatocyte volume and liver volume by computed tomography. Am J Gastroenterol 2001; 96: 541-546.
6. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906. (Pubitemid 40824701)
7. Bennink RJ, Dinant S, Erdogan D, Heijnen BH, Straatsburg IH, van Vliet AK, van Gulik TM: Preoperative assessment of postoperative remnant liver function using hepatobiliary scintigraphy. J Nucl Med 2004; 45: 965-971. (Pubitemid 47611683)
8. De Graaf W, van Lienden KP, Dinant S, Roelofs JJ, Busch OR, Gouma DJ, Bennink RJ, van Gulik TM: Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection. J Gastrointest Surg 2010; 14: 369-378.
9. Kudo M: Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Oncology 2010; 78(suppl 1):87-93.
10. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012; 1: 41-50.
11. Ricke J, Seidensticker M, Mohnike K: Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: Current guidelines and future prospects for radiological imaging. Liver Cancer 2012; 1: 51-58.
12. Goshima S, Kanematsu M, Kobayashi T, Furukawa T, Zhang X, Fujita H, Watanabe H, Kondo H, Moriyama N, Bae KT: Staging hepatic fibrosis: Computer-aided analysis of hepatic contours on Gd-EOB-DTPA-enhanced hepatocyte-phase MR images. Hepatology 2012; 55: 328-329.
13. Lipson JA, Qayyum A, Avrin DE, Westphalen A, Yeh BM, Coakley FV: CT and MRI of hepatic contour abnormalities. AJR Am J Roentgenol 2005; 184: 75-81. (Pubitemid 40040908)
14. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Dore CJ, Goldin RD, Bell JD, Taylor-Robinson SD: Hepatic triglyceride content and its relation to body adiposity: A magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005; 54: 122-127. (Pubitemid 40007230)
15. Cho SG, Kim MY, Kim HJ, Kim YS, Choi W, Shin SH, Hong KC, Kim YB, Lee JH, Suh CH: Chronic hepatitis: In vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings. Radiology 2001; 221: 740-746. (Pubitemid 33101766)
16. Bonekamp S, Kamel I, Solga S, Clark J: Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? J Hepatol 2009; 50: 17-35.
17. Tam HH, Collins DJ, Wallace T, Brown G, Riddell A, Koh DM: Segmental liver hyperintensity in malignant biliary obstruction on diffusion-weighted magnetic resonance imaging: Associated magnetic resonance imaging findings and relationship with serum alanine aminotransferase levels. Br J Radiol 2012; 85: 22-28.
18. Heye T, Yang SR, Bock M, Brost S, Weigand K, Longerich T, Kauczor HU, Hosch W: MR relaxometry of the liver: Significant elevation of T 1 relaxation time in patients with liver cirrhosis. Eur Radiol 2012; 22: 1224-1232.
19. Van Beers BE, Pastor CM, Hussain HK: Primovist, eovist: What to expect? J Hepatol 2012; 57: 421-429.
20. Ringe KI, Husarik DB, Gupta RT, Boll DT, Merkle EM: Hepatobiliary transit times of gadoxetate disodium (Primovist) for protocol optimization of comprehensive magnetic resonance imaging of the biliary system Ywhat is normal? Eur J Radiol 2011; 79: 201-205.
21. Tamada T, Ito K, Sone T, Kanki A, Sato T, Higashi H: Gd-EOB-DTPA-enhanced magnetic resonance imaging: Evaluation of biliary and renal excretion in normal and cirrhotic livers. Eur J Radiol 2011; 80:e207-e211.
22. Takao H, Akai H, Tajima T, Kiryu S, Watanabe Y, Imamura H, Akahane M, Yoshioka N, Kokudo N, Ohtomo K: Magnetic resonance imaging of the biliary tract with Gd-EOB-DTPA: Effect of liver function on signal intensity. Eur J Radiol 2011; 77: 325-329.
23. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D: Contrastenhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: Visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 2008; 18: 1577-1586.
24. Wibmer A, Aliya Q, Steininger R, Trauner M, Maresch J, Mühlbacher F, Ba-Ssalamah A: Liver transplantation: Impaired biliary excretion of gadoxate is associated with an inferior one-year retransplantation-free survival. Invest Radiol 2012; 47: 353-358.
25. Smith AD, Veniero JC: Gd-EOB-DTPA as a functional MR cholangiography contrast agent: Imaging gallbladder filling in patients with and without hepatobiliary dysfunction. J Comput Assist Tomogr 2011; 35: 439-445.
26. Lee NK, Kim S, Lee JW, Lee SH, Kang DH, Kim GH, Seo HI: Biliary magnetic resonance imaging with Gd-EOB-DTPA and its clinical applications. Radiographics 2009; 29: 1707-1724.
27. Lee NK, Kim S, Kim GH, Heo J, Seo HI, Kim TU, Kang DH: Significance of the 'delayed hyperintense portal vein sign' in the hepatobiliary phase magnetic resonance imaging obtained with Gd-EOB-DTPA. J Magn Reson Imaging 2012; 36: 678-685.
28. Tajima T, Takao H, Akai H, Kiryu S, Imamura H, Watanabe Y, Shibahara J, Kokudo N, Akahane M, Ohtomo K: Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acidenhanced magnetic resonance imaging. J Comput Assist Tomogr 2010; 34: 362-366.
29. Motosugi U, Ichikawa T, Oguri M, Sano K, Sou H, Muhi A, Matsuda M, Fujii H, Enomoto N, Araki T: Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced magnetic resonance imaging: Comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 2011; 29: 1047-1052.
30. Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N, Bae KT: Staging hepatic fibrosis: Comparison of gadoxetate disodium-enhanced and diffusionweighted magnetic resonance imaging Y preliminary observations. Radiology 2011; 259: 142-150.
31. Yamada A, Hara T, Li F, Fujinaga Y, Ueda K, Kadoya M, Doi K: Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced magnetic resonance imaging. Radiology 2011; 260: 727-733.
32. Tamada T, Ito K, Higaki A, Yoshida K, Kanki A, Sato T, Higashi H, Sone T: Gd-EOBDTPA-enhanced magnetic resonance imaging: Evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol 2011; 80:e311-e316.
33. Nishie A, Ushijima Y, Tajima T, Asayama Y, Ishigami K, Kakihara D, Nakayama T, Takayama Y, Okamoto D, Abe K, Obara M, Yoshimitsu K, Honda H: Quantitative analysis of liver function using superparamagnetic iron oxide- and Gd-EOB-DTPA-enhanced magnetic resonance imaging: Comparison with technetium-99m galactosyl serum albumin scintigraphy. Eur J Radiol 2012; 81: 1100-1104.
34. Nakamura S, Awai K, Utsunomiya D, Namimoto T, Nakaura T, Morita K, Yamashita Y: Chronological evaluation of liver enhancement in patients with chronic liver disease at Gd-EOB-DTPA-enhanced 3T magnetic resonance imaging: Does liver function correlate with enhancement? Jpn J Radiol 2012; 30: 25-33.
35. Cho SH, Kang UR, Kim JD, Han YS, Choi DL: The value of gadoxetate disodium-enhanced magnetic resonance imaging for predicting posthepatectomy liver failure after major hepatic resection: A preliminary study. Eur J Radiol 2011; 80:e195-e200.
36. Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J: Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol 2011; 46: 556-566.
37. Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, Kudo M, Kitagaki H, Murakami T: Estimation of liver function using T 1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol 2011; 46: 277-283.
38. Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, Ishii K, Tanigawa N, Imai Y, Kudo M, Murakami T: Estimation of liver function using T 2 . mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. Eur J Radiol 2012; 81: 1460-1464.
39. Materne R, Smith AM, Peeters F, Dehoux JP, Keyeux A, Horsmans Y, Van Beers BE: Assessment of hepatic perfusion parameters with dynamic magnetic resonance imaging. Magn Reson Med 2002; 47: 135-142. (Pubitemid 34019702)
40. Nanashima A, Yamaguchi H, Shibasaki S, Morino S, Ide N, Takeshita H, Sawai T, Nakagoe T, Nagayasu T, Ogawa Y: Relationship between indocyanine green test and technetium-99m galactosyl serum albumin scintigraphy in patients scheduled for hepatectomy: Clinical evaluation and patient outcome. Hepatol Res 2004; 28: 184-190. (Pubitemid 38351912)
41. Sommer WH, Sourbron S, Huppertz A, Ingrisch M, Reiser MF, Zech CJ: Contrast agents as a biological marker in magnetic resonance imaging of the liver: Conventional and new approaches. Abdom Imaging 2012; 37: 164-179.
42. Nilsson H, Blomqvist L, Douglas L, Nordell A, Jonas E: Assessment of liver function in primary biliary cirrhosis using Gd-EOBDTPA-enhanced liver magnetic resonance imaging. HPB (Oxford) 2010; 12: 567-576.
43. Nilsson H, Nordell A, Vargas R, Douglas L, Jonas E, Blomqvist L: Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2009; 29: 1323-1331.
44. Chen BB, Hsu CY, Yu CW, Wei SY, Kao JH, Lee HS, Shih TT: Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol 2012; 22: 171-180.